medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2014, Number 4

<< Back Next >>

An Med Asoc Med Hosp ABC 2014; 59 (4)

Mediastinal Castleman’s disease evaluated by 18F-FDG PET/CT

Olarte CMÁ, Padilla RÁ, García OJR, Martínez MR

Language: Spanish
References: 34
Page: 279-284
PDF size: 349.46 Kb.


ABSTRACT

Castleman’s disease or angiofollicular hyperplasia is an atypical lymphoproliferative disorder. First described in 1956 by Benjamin Castleman, it is considered a heterogeneous disease that can be classified in two clinical groups: unicentric or localized, and multicentric or systemic. Histologically, there are three variants: hyaline vascular, plasma cell, and a mix of both. Its etiology remains unknown, but it is related with a chronic antigenic stimulation caused by viral infections, which determines the reactive lymphoid hyperplasia that distinguishes this entity. Approximately 70% of these tumors grow in the mediastinum. Castleman’s disease does not have demonstrable characteristics by imagenological studies, so biopsy provides the accurate diagnosis. Due to the fact that 18F-FDG PET/CT (positron emission tomography/computed tomography) allows an anatomical and metabolic evaluation, especially for lymphoproliferative disorders, it is an excellent diagnostic tool to determine the location and extension of Castleman’s disease, as well as to identify the optimal site for biopsy and thereby reduce the morbidity associated with improperly performed biopsies. In the same way, this modality enables to adequately stage the patient prior to making a therapeutic decision, and also allows to evaluate the response to treatment and to follow up the disease. Objective: is to identify the metabolic behavior of mediastinal Castleman’s disease and evaluate the usefulness of 18F-FDG PET/CT as a tool to identify the lesion and the extent of disease, and in assessing response to treatment.


REFERENCES

  1. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph node hyperplasia resembling thymoma. Cancer. 1956; 9: 822.

  2. Casper C. The etiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol. 2005; 129: 3-17.

  3. Shaidi H, Myers J, Kuale P. Castleman’s disease. Mayo Clin Proc. 1995; 70: 969-977.

  4. Scwarzenberg H. Castleman’s disease: evaluation of 338 cases. Rofo Fortschr Geb Rontgenstr Neven Bildgeb Verfahr. 1995; 163: 474-479.

  5. Hengge UR et al. Update on Kaposi’s sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman’s disease, and pleural effusion lymphoma. Lancet Infect Dis. 2002; 2: 344-352.

  6. Parravicini C et al. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman’s disease. Am J Pathol. 1997; 151: 1517-1522.

  7. Foss H D et al. Expression of vascular endothelial growth factor in lymphomas and Castleman’s disease. J Pathol. 1997; 183: 44-50.

  8. Schulte KM, Talat N. Castleman’s disease-a two compartment model of HHV8 infection. Nat Rev Clin Oncol. 2010; 7: 533-543.

  9. Goldberg MA, DeLuca SA. Castleman’s disease. Am Fani Physician. 1989; 40: 151-153.

  10. Viveros-Añorbe M, Sánchez-Marl JF. Enfermedad de Castleman. Reporte de un caso en adolescente. Anales Médicos, Hospital ABC. 2001; 46: 193-196.

  11. Murphy SP, Nathan MA, Karwal MW. FDG-PET Appearance of pelvic Castleman’s disease. J Nucl Med. 1997; 38: 1211-1212.

  12. Yamashita Y, Ilirai T, Matsukawa T, Ogata I, Takahashi M. Radiological presentations of Castleman’s disease. Compud Med Imaging Graph. 1993; 17: 107-117.

  13. Enomoto K et al. Unicentric and multicentric Castleman’s disease. Br J Radiol. 2007; 80: 24-26.

  14. Griffeth LK, Dehdashti F, McGuire AH et al. PET evaluation of soft-tissue masses with fluorine-18-fluoro-2-deoxy-D-glucose. Radiology. 1992; 182: 185-194.

  15. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004; 231: 305-332.

  16. Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med. 1995; 36: 1836-1839.

  17. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[18F]-fluoro-2-deoxy D-glucose: correlation with CT. Radiology. 1994; 190: 111-116.

  18. Todd MB, Carolyn C, Meltzer D, Townsend W. PET/CT: form and function. Radiology. 2007; 242: 360-385.

  19. Cabrera A, Gámez C, Urreta JC. Tomografía por emisión de positrones (PET) en oncología clínica (Parte II). Rev Esp Med Nuclear. 2002; 21 (2): 131-147.

  20. Dispenzieri A. Castleman disease. Cancer Treat Res. 2008; 142: 293-330.

  21. Mainolfi C et al. Positron-emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Radiol Med. 1998; 95 (1-2): 98-104.

  22. Loachim H. Angiofollicular lymph node hyperplasia. Lymph node biopsy. Philadelphia: Lippincott Company; 1982.

  23. Soulier J, Grollet L, Oksenhendler E. Molecular analysis of clonality in Castleman’s disease. Blood. 1995; 86: 1131-1138.

  24. Chen CH, Liu HC, Hung TT, Liu TP. Possible roles of Epstein-Barr virus in Castleman disease. J Cardiothorac Surg. 2009; 4 (31): 1-5.

  25. Seo HY, Kim EB, Kim JW. Complete remission in a patient with human herpes virus-8 negative multicentric Castleman disease using CHOP chemotherapy. Cancer Res Treat. 2009; 41 (2): 104-107.

  26. Dham A, Peterson B. Castleman disease. Curr Opin Hematol. 2007; 14: 354-359.

  27. Newlon J, Couch M, Brennan J. Castleman’s disease: three case reports and a review of the literature. Ear Nose Throat J. 2007; 86: 414-4118.

  28. Roca B. Castleman’s disease. A review. AIDS Rev. 2009; 11: 3-7.

  29. Kojima M, Motoori T, Asano S, Nakamura S. Histological diversity of reactive and atypical proliferative lymph node lesions in systemic lupus erythematosus patients. Pathol Res Pract. 2007; 203: 423-431.

  30. McAdams HP, Rosado de Christenson M. Castleman disease of the thorax: radiologic features with clinical and histopathologic correlation. Radiology. 1998; 209: 221-228.

  31. Bakheet SM, Powe J. Benign causes of 18-FDG uptake on whole body imaging. Semin Nucl Med. 1998; 28: 352-358.

  32. Leskinen-Kallio S, Ruotsalainen U, Nagren K, Teras M, Joensuu H. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin’s lymphoma: a PET study. J Nucl Med. 1991; 32: 1211-1218.

  33. Zhuang H, Pourdehnad M, Lambright ES. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001; 42: 1412-1417.

  34. Nordstrom G, Tewfik HH, Latourette HB. Plasma cell giant lymph node hyperplasia responding to radiation therapy. Am J Roentgenol. 1978; 130: 169-171.




2020     |     www.medigraphic.com